Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Amit Sanyal, MD: A Clinician’s Perspective

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Jun
27
Today In Oncology
Existing Cardioprotective Agents Provide Limited Benefits for Patients With Cancer
First-Line Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Tumors
CNS Prophylaxis With High-Dose Methotrexate in Ultra–High-Risk Large B-Cell Lymphoma
FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC
Changes in AI Mammogram Risk Scores Over Time May Help to Predict Future Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo